As an industry, we’ve done a lot thinking about the impact of COVID-19 on research that informs the development and commercialization of safe and effective medical devices. In this webisode, Bold Insight’s Managing Partner Korey Johnson describes why at least some of this research must be considered essential, and what the implications would be if this were not the case given the likelihood that COVID-19 concerns will likely be around for some time.
